Advertisement
UK markets close in 2 hours 32 minutes

  • FTSE 100

    8,238.39
    -24.36 (-0.29%)
     

  • FTSE 250

    20,719.16
    -181.33 (-0.87%)
     

  • AIM

    800.65
    -4.51 (-0.56%)
     

  • GBP/EUR

    1.1749
    +0.0011 (+0.10%)
     

  • GBP/USD

    1.2765
    -0.0040 (-0.31%)
     

  • Bitcoin GBP

    53,995.70
    -581.20 (-1.06%)
     

  • CMC Crypto 200

    1,445.26
    -1.89 (-0.13%)
     

  • S&P 500

    5,283.40
    +5.89 (+0.11%)
     

  • DOW

    38,571.03
    -115.27 (-0.30%)
     

  • CRUDE OIL

    73.02
    -1.20 (-1.62%)
     

  • GOLD FUTURES

    2,353.10
    -16.20 (-0.68%)
     

  • NIKKEI 225

    38,837.46
    -85.54 (-0.22%)
     

  • HANG SENG

    18,444.11
    +41.11 (+0.22%)
     

  • DAX

    18,494.78
    -113.38 (-0.61%)
     

  • CAC 40

    7,973.17
    -24.85 (-0.31%)
     
Pensions:

The future of life time allowance

How Labour and Conservative policies will impact pension planning

Bruker Corporation to Host Investor Webinar on May 17, 2024

Business Wire
·2-min read

BILLERICA, Mass., May 09, 2024--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) today announced it intends to hold an Investor Webinar from 10 am to about 12 noon Eastern Daylight Time (EDT) on May 17, 2024, to provide additional insights into its three recent acquisitions of Chemspeed, ELITech, and of the NanoString business. Bruker also expects to provide an update to its medium-term financial outlook.

The Investor Webinar will include presentations by CEO Frank H. Laukien, CFO Gerald Herman, and by the leaders of these three new Bruker businesses, all followed by a live Q&A session for analysts and investors.

A link to the Investor Webinar will be available in the Events & Presentations section of the Company’s Investor Relations website at https://ir.bruker.com. A replay will be available on Bruker’s Investor Relations website after the conclusion of the event.

ADVERTISEMENT

About Bruker Corporation – Leader of the Post-Genomic Era (Nasdaq: BRKR)

Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker’s high-performance scientific instruments and high-value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in applied and biopharma applications, in microscopy and nanoanalysis, as well as in industrial and cleantech research, and next-gen semiconductor metrology in support of AI. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit www.bruker.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240509874955/en/

Contacts

Justin Ward
Sr. Director, Investor Relations & Corporate Development
Bruker Corporation
T: +1 (978) 313-5800
E: Investor.Relations@bruker.com